White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).
“Immune checkpoint inhibitors such as nivolumab and pembrolizumab significantly improve overall survival in some — but not all — patients with non-small cell lung cancer (NSCLC),” said lead author Dr Marcello Tiseo, Coordinator of DMT Thoracic Oncology, University Hospital of Parma, Italy.
